Engineering the Cellular Protein Secretory Pathway for Enhancement of Recombinant Tissue Plasminogen Activator Expression in Chinese Hamster Ovary Cells: Effects of CERT and XBP1s Genes
Abstract
Cell line development is the most critical and also the most time-consuming step in the production of recombinant therapeutic proteins. In this regard, a variety of vector and cell engineering strategies have been developed for generating high-producing mammalian cells; however, the cell line engineering approach seems to show various results on different recombinant protein producer cells. In order to improve the secretory capacity of a recombinant tissue plasminogen activator (t-PA)-producing Chinese hamster ovary (CHO) cell line, we developed cell line engineering approaches based on the ceramide transfer protein (CERT) and X-box binding protein 1 (XBP1) genes. For this purpose, CERT S132A, a mutant form of CERT that is resistant to phosphorylation, and XBP1s were overexpressed in a recombinant t-PA-producing CHO cell line. Overexpression of CERT S132A increased the specific productivity of t-PA-producing CHO cells up to 35%. In contrast, the heterologous expression of XBP1s did not affect the t-PA expression rate. Our results suggest that CERTS132A- based secretion engineering could be an effective strategy for enhancing recombinant t- PA production in CHO cells.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Overexpression of the CERT S132A mutant improved production of t-PA, human serum albumin and monoclonal antibodies in industrial cell lines.
“Similarly, overexpression of ceramidetransfer protein (CERT) S132A mutant, which is responsible for the transfer of ceramide from the ER to the Golgi and for sphingomyelin synthesis, also improved production of t-PA, human serum albumin and monoclonal antibodies in industrial cell lines (Florin et al., 2009;Rahimpour et al., 2013).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Rahimpour et al., 2013
Cited by
Sorted by citations
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296 · see citing works
- Authors
- Rahimpour, A.
- Affiliations
- Pasteur Institute of Iran (IR)
- Corresponding author
- Rahimpour, Azam
- ORCID
- Rahimpour, Azam
- Venue
- Journal of Microbiology and Biotechnology
- Published
- 2013-08-28
- Volume
- 23
- Issue
- 8
- Pages
- 1116-1122
- ISSN
- 1017-7825 (ISSN-L)
- 1738-8872
- OpenAlex
- W1966212700
- Cited by
- 30
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 4 · 2014: 4
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Microbiology and Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- tissue plasminogen activator, recombinant protein secretion, ceramide transfer protein, XBP1, unfolded protein response, protein overexpression
- MeSH terms
- Animals, Carrier Proteins, Cricetulus, DNA-Binding Proteins, Female, Cricetinae, Tissue Plasminogen Activator, Recombinant Proteins, Gene Expression, CHO Cells, Secretory Pathway, Metabolic Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review